@article{070ce16592a0481bb26fee8740f5edd3,
title = "18F-Fluciclovine Uptake in a Ureterocele",
abstract = "A 60-year-old man with prostate adenocarcinoma status post radical prostatectomy and bilateral pelvic lymph node dissection referred for restaging 18F-fluciclovine PET/CT due to rising serum prostate-specific antigen levels (1.1 ng/mL at that time of imaging). PET/CT images were obtained from the proximal thighs to the vertex of the skull approximately 3 to 5 minutes after the IV administration of 347.8 MBq (9.4 mCi) of 18F-fluciclovine. PET/CT imaging demonstrated a focus of abnormally increased 18F-fluciclovine uptake at the right ureterovesical junction. Subsequent MRI of the pelvis revealed that this focus corresponded to a benign ureterocele.",
keywords = "F-fluciclovine, PET/CT, false-positive, pitfalls, ureterocele",
author = "Ryan Bitar and Janio Szklaruk and Lucia Martiniova and Zurita, {Amado J.} and Chery, {Lisly J.} and Gregory Ravizzini",
note = "Funding Information: Received for publication March 13, 2020; revision accepted July 23, 2020. From the *The University of Texas Health Science Center at San Antonio, San Antonio; and †Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Conflicts of interest and sources of funding: G.R. is a recipient of research grants from Blue Earth Diagnostics. None declared to all other authors. Correspondence to: Gregory C. Ravizzini, MD, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1483, Houston, TX 77030. E-mail: gravizzini@mdanderson.org. Copyright {\textcopyright} 2020 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0363-9762/21/4601–00e3 DOI: 10.1097/RLU.0000000000003272",
year = "2021",
doi = "10.1097/RLU.0000000000003272",
language = "English (US)",
volume = "46",
pages = "E3--E5",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "1",
}